COMPANY

Sano Chemicals Inc

HQ: Bryan, TX source · sanochemicals.com ↗ · Southwest

Clinical Phase 2

Also known as Sano Chemicals · 9 sources

Keywords: infectious disease infectious diseases Vulvovaginal Candidiasis candidiasis

Location: Bryan, TX · source · May 16, 2024

Profile checked Oct 10, 2026

1Trials (company is sponsor)8NIH grants

Timeline

Jun 4, 2026 Trial start Phase 2: Biweekly Long-term Occidiofungin Study for Suppression of Mycotic Recurrence source ↗

Upcoming milestones

Dec 31, 2026 (ESTIMATED) · Phase 2 · Biweekly Long-term Occidiofungin Study for Suppression of Mycotic Recurrence · NCT07521137

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 1

Record	Title	Phase	Status	Start	Primary completion
NCT07521137	Biweekly Long-term Occidiofungin Study for Suppression of Mycotic Recurrence	Phase 2	Recruiting	Jun 4, 2026	Dec 31, 2026 (estimated)

NIH awards 8

Annual award amounts. Total $4.2M.

Jul 5, 2024 NIH award 1R42AI184022-01 FY2024: $300,000 awarded for that fiscal year; activity R42 (STTR); PI SMITH, JAMES LEIF; recipient as written: SANO CHEMICALS, INC, COLLEGE STATION, TX. Preclinical Development of Occidiofu source ↗
Apr 27, 2021 NIH award 5R42AI131792-04 FY2021: $930,515 awarded for that fiscal year; activity R42 (STTR); PI SMITH, JAMES LEIF; recipient as written: SANO CHEMICALS, INC, COLLEGE STATION, TX. Preclinical Development of OCF001 fo source ↗
Aug 11, 2020 NIH award 1R41AI149803-01A1 FY2020: $233,066 awarded for that fiscal year; activity R41 (STTR); PI SMITH, JAMES LEIF; recipient as written: SANO CHEMICALS, INC, COLLEGE STATION, TX. A Novel Therapeutic Agent for the source ↗
Apr 16, 2020 NIH award 5R42AI131792-03 FY2020: $965,515 awarded for that fiscal year; activity R42 (STTR); PI SMITH, JAMES LEIF; recipient as written: SANO CHEMICALS, INC, COLLEGE STATION, TX. Preclinical Development of OCF001 fo source ↗
Mar 21, 2019 NIH award 2R42AI131792-02A1 FY2019: $983,345 awarded for that fiscal year; activity R42 (STTR); PI SMITH, JAMES LEIF; recipient as written: SANO CHEMICALS, INC, COLLEGE STATION, TX. Preclinical Development of OCF001 source ↗
Feb 17, 2017 NIH award 5R41AI122441-02 FY2017: $234,170 awarded for that fiscal year; activity R41 (STTR); PI SMITH, JAMES LEIF; recipient as written: SANO CHEMICALS, INC, COLLEGE STATION, TX. Optimization of the Production and I source ↗
Feb 14, 2017 NIH award 1R41AI131792-01 FY2017: $224,939 awarded for that fiscal year; activity R41 (STTR); PI SMITH, JAMES LEIF; recipient as written: SANO CHEMICALS, INC, COLLEGE STATION, TX. Lead Compound Discovery from Enginee source ↗
Mar 11, 2016 NIH award 1R41AI122441-01A1 FY2016: $295,381 awarded for that fiscal year; activity R41 (STTR); PI SMITH, JAMES LEIF; recipient as written: SANO CHEMICALS, INC, COLLEGE STATION, TX. Optimization of the Production and source ↗